Zhejiang Yatai Pharmaceutical Co., Ltd. (002370) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Yatai Pharmaceutical Co., Ltd.

Why is Zhejiang Yatai Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of -1.08% and Operating profit at 14.40% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 1.39% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of -1.08% and Operating profit at 14.40% over the last 5 years

INTEREST(HY) At CNY 32.18 MM has Grown at 84.46%
PRE-TAX PROFIT(Q) At CNY -6.75 MM has Fallen at -120.88%
NET PROFIT(Q) At CNY -6.54 MM has Fallen at -120.33%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Yatai Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Zhejiang Yatai Pharmaceutical Co., Ltd.

92.35%

2.21

57.75%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.08%

EBIT Growth (5y)

14.40%

EBIT to Interest (avg)

-1.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

0.32

Tax Ratio

1.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

1.39%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.74

EV to EBIT

-107.51

EV to EBITDA

2727.58

EV to Capital Employed

6.76

EV to Sales

11.04

PEG Ratio

0.05

Dividend Yield

ROCE (Latest)

-6.29%

ROE (Latest)

11.39%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET PROFIT(HY)

Higher at CNY 104.09 MM

ROCE(HY)

Highest at 15.45%

DEBT-EQUITY RATIO (HY)

Lowest at -53.74 %

RAW MATERIAL COST(Y)

Fallen by -31% (YoY

-28What is not working for the Company

INTEREST(HY)

At CNY 32.18 MM has Grown at 84.46%

PRE-TAX PROFIT(Q)

At CNY -6.75 MM has Fallen at -120.88%

NET PROFIT(Q)

At CNY -6.54 MM has Fallen at -120.33%

OPERATING CASH FLOW(Y)

Lowest at CNY 26.97 MM

CASH AND EQV(HY)

Lowest at CNY 1,243.07 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.43 times

NET SALES(Q)

At CNY 76.23 MM has Fallen at -9.06%

OPERATING PROFIT(Q)

Lowest at CNY -10.78 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -14.13 %

Here's what is working for Zhejiang Yatai Pharmaceutical Co., Ltd.

Debt-Equity Ratio

Lowest at -53.74 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -31% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Yatai Pharmaceutical Co., Ltd.

Interest

At CNY 32.18 MM has Grown at 84.46%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Pre-Tax Profit

At CNY -6.75 MM has Fallen at -120.88%

over average net sales of the previous four periods of CNY 32.35 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -6.54 MM has Fallen at -120.33%

over average net sales of the previous four periods of CNY 32.15 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY 26.97 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

At CNY 76.23 MM has Fallen at -9.06%

over average net sales of the previous four periods of CNY 83.83 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY -10.78 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -14.13 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at CNY 1,243.07 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 2.43 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio